Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.58
SNY's Cash to Debt is ranked higher than
54% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. SNY: 0.58 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: 10.62
Current: 0.58

0.14
10.62
Equity to Asset 0.59
SNY's Equity to Asset is ranked higher than
64% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. SNY: 0.59 )
SNY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.65
Current: 0.59

0.48
0.65
Interest Coverage 8.34
SNY's Interest Coverage is ranked higher than
52% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. SNY: 8.34 )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 8.34

7.88
19.65
F-Score: 4
Z-Score: 2.12
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.33
SNY's Operating margin (%) is ranked higher than
84% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. SNY: 15.33 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 15.33

15.25
38.21
Net-margin (%) 11.16
SNY's Net-margin (%) is ranked higher than
81% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. SNY: 11.16 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 11.16

7.92
25.8
ROE (%) 6.53
SNY's ROE (%) is ranked higher than
70% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. SNY: 6.53 )
SNY' s 10-Year ROE (%) Range
Min: 4.84   Max: 32.83
Current: 6.53

4.84
32.83
ROA (%) 3.87
SNY's ROA (%) is ranked higher than
71% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. SNY: 3.87 )
SNY' s 10-Year ROA (%) Range
Min: 2.33   Max: 21.3
Current: 3.87

2.33
21.3
ROC (Joel Greenblatt) (%) 32.17
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. SNY: 32.17 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 32.17   Max: 111.43
Current: 32.17

32.17
111.43
Revenue Growth (%) -1.50
SNY's Revenue Growth (%) is ranked higher than
58% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. SNY: -1.50 )
SNY' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 27.4
Current: -1.5

-1.5
27.4
EBITDA Growth (%) -3.70
SNY's EBITDA Growth (%) is ranked higher than
64% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. SNY: -3.70 )
SNY' s 10-Year EBITDA Growth (%) Range
Min: -3.7   Max: 35.7
Current: -3.7

-3.7
35.7
EPS Growth (%) -12.70
SNY's EPS Growth (%) is ranked higher than
61% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. SNY: -12.70 )
SNY' s 10-Year EPS Growth (%) Range
Min: -12.7   Max: 41.2
Current: -12.7

-12.7
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SNY Guru Trades in Q1 2013

James Barrow 5,417,861 sh (+15.63%)
Sarah Ketterer 77,131 sh (+14.62%)
HOTCHKIS & WILEY 4,578,740 sh (+11.45%)
Manning & Napier Advisors, Inc 275,034 sh (+8.86%)
Jean-Marie Eveillard 808,762 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
John Hussman 22,100 sh (unchged)
Meryl Witmer 7,000 sh (unchged)
PRIMECAP Management 2,123,431 sh (-1.96%)
Third Avenue Management 12,485 sh (-2.35%)
Ken Fisher 12,857,867 sh (-2.43%)
Dodge & Cox 44,670,455 sh (-3.39%)
Murray Stahl 26,000 sh (-3.7%)
Charles Brandes 2,150,989 sh (-12.52%)
NWQ Managers 8,381,844 sh (-24.79%)
» More
Q2 2013

SNY Guru Trades in Q2 2013

Chuck Royce 1,000 sh (New)
Mario Gabelli 4,500 sh (New)
Manning & Napier Advisors, Inc 315,839 sh (+14.84%)
Sarah Ketterer 88,394 sh (+14.6%)
Third Avenue Management 13,190 sh (+5.65%)
PRIMECAP Management 2,184,231 sh (+2.86%)
Murray Stahl 26,000 sh (unchged)
Meryl Witmer 7,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 4,063,675 sh (unchged)
John Hussman 22,100 sh (unchged)
Ken Fisher 12,808,861 sh (-0.38%)
Dodge & Cox 44,151,787 sh (-1.16%)
James Barrow 5,199,519 sh (-4.03%)
Jean-Marie Eveillard 653,662 sh (-19.18%)
Charles Brandes 1,713,266 sh (-20.35%)
HOTCHKIS & WILEY 3,633,907 sh (-20.64%)
NWQ Managers 5,607,262 sh (-33.1%)
» More
Q3 2013

SNY Guru Trades in Q3 2013

James Barrow 21,466,988 sh (+312.86%)
Mario Gabelli 5,950 sh (+32.22%)
HOTCHKIS & WILEY 4,786,334 sh (+31.71%)
Sarah Ketterer 114,118 sh (+29.1%)
Third Avenue Management 13,830 sh (+4.85%)
PRIMECAP Management 2,284,031 sh (+4.57%)
Manning & Napier Advisors, Inc 323,315 sh (+2.37%)
Ken Fisher 12,828,009 sh (+0.15%)
John Hussman 22,100 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Jean-Marie Eveillard 653,662 sh (unchged)
Chuck Royce Sold Out
Dodge & Cox 43,966,249 sh (-0.42%)
Charles Brandes 1,701,970 sh (-0.66%)
NWQ Managers 5,425,020 sh (-3.25%)
Warren Buffett 3,905,875 sh (-3.88%)
» More
Q4 2013

SNY Guru Trades in Q4 2013

Sarah Ketterer 431,317 sh (+277.96%)
HOTCHKIS & WILEY 5,912,375 sh (+23.53%)
Charles Brandes 2,013,300 sh (+18.29%)
Third Avenue Management 16,105 sh (+16.45%)
NWQ Managers 5,832,760 sh (+7.52%)
James Barrow 22,645,140 sh (+5.49%)
Jean-Marie Eveillard 654,462 sh (+0.12%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman 22,100 sh (unchged)
Ken Fisher 12,818,390 sh (-0.07%)
PRIMECAP Management 2,281,231 sh (-0.12%)
Dodge & Cox 43,628,729 sh (-0.77%)
Manning & Napier Advisors, Inc 312,008 sh (-3.5%)
Mario Gabelli 4,500 sh (-24.37%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2013-12-31 Add 18.29%0.2%$48.75 - $54 $ 52.342%2013300
Mario Gabelli 2013-12-31 Reduce -24.37%$48.75 - $54 $ 52.342%4500
James Barrow 2013-09-30 Add 312.86%1.29%$47.64 - $53.24 $ 52.343%21466988
Mario Gabelli 2013-09-30 Add 32.22%$47.64 - $53.24 $ 52.343%5950
Charles Brandes 2013-06-30 Reduce -20.35%0.26%$49.77 - $55.64 $ 52.34-2%1713266
Mario Gabelli 2013-06-30 New Buy$49.77 - $55.64 $ 52.34-2%4500
Charles Brandes 2012-09-30 Reduce -25.37%0.41%$36.81 - $44.6 $ 52.3429%2982819
David Dreman 2012-09-30 Sold Out 0.09%$36.81 - $44.6 $ 52.3429%0
John Hussman 2012-06-30 Add 22.62%$33.4 - $39.06 $ 52.3446%27100
PRIMECAP Management 2012-03-31 Add 141.26%0.08%$35.32 - $38.92 $ 52.3449%2222692
George Soros 2011-12-31 Sold Out 0.11%$31.72 - $37.45 $ 52.3452%0
James Barrow 2011-12-31 Add 26.83%0.08%$31.72 - $37.45 $ 52.3452%4501475
James Barrow 2011-09-30 Add 83.96%0.13%$31.5 - $40.08 $ 52.3446%3549200
George Soros 2011-09-30 New Buy0.11%$31.5 - $40.08 $ 52.3446%201400
Dodge & Cox 2011-06-30 Add 6.63%0.16%$35.68 - $40.58 $ 52.3438%54287695
James Barrow 2011-06-30 Add 43.65%0.05%$35.68 - $40.58 $ 52.3438%1929300
David Dreman 2011-06-30 Add 38.36%0.02%$35.68 - $40.58 $ 52.3438%96767
John Hussman 2011-06-30 Add 39.68%$35.68 - $40.58 $ 52.3438%17600
Dodge & Cox 2011-03-31 Add 6.45%0.12%$31.87 - $36.2 $ 52.3453%50912344
James Barrow 2011-03-31 New Buy0.1%$31.87 - $36.2 $ 52.3453%1343100
David Dreman 2011-03-31 Add 34.03%0.01%$31.87 - $36.2 $ 52.3453%69940
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Bill Nygren Comments on Sanofi
Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%. Read more...
Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...
Warren Buffett Shows Changes to International Stocks: Tesco, Munich Re, Sanofi, POSCO
Warren Buffett (Trades, Portfolio) reported the holding changes at Berkshire Hathaway (BRK.A)(BRK.B) last month, but he did not include his foreign stocks, as he is not required to by the SEC. Once a year, in his annual letters, however, he gives a glimpse of his international dealings by reporting the status of all his equity positions exceeding $1 billion in value. The latest letter, reported last week, revealed some notable changes in his international holdings. Read more...
Top Guru-Held European Companies as of the Second Quarter
By using the Aggregated Portfolio Screener, we filtered through the 51 highest rated gurus to find out what international companies they liked the best. The following companies are each held by 10 gurus as of the second quarter. [b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.10
SNY's P/E(ttm) is ranked higher than
67% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. SNY: 27.10 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 27.1

9.64
38.97
P/B 1.70
SNY's P/B is ranked higher than
79% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. SNY: 1.70 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 7.05
Current: 1.7

1.11
7.05
P/S 3.05
SNY's P/S is ranked higher than
53% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. SNY: 3.05 )
SNY' s 10-Year P/S Range
Min: 1.72   Max: 5.26
Current: 3.05

1.72
5.26
PFCF 18.20
SNY's PFCF is ranked higher than
79% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. SNY: 18.20 )
SNY' s 10-Year PFCF Range
Min: 6.66   Max: 85.69
Current: 18.2

6.66
85.69
EV-to-EBIT 20.40
SNY's EV-to-EBIT is ranked higher than
62% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. SNY: 20.40 )
SNY' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 204.2
Current: 20.4

9.4
204.2
PEG 29.80
SNY's PEG is ranked lower than
66% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 29.80 )
SNY' s 10-Year PEG Range
Min: 0.27   Max: 29.8
Current: 29.8

0.27
29.8
Shiller P/E 21.40
SNY's Shiller P/E is ranked higher than
73% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. SNY: 21.40 )
SNY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 25.2
Current: 21.4

13.35
25.2

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.49
SNY's Dividend Yield is ranked higher than
94% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. SNY: 2.49 )
SNY' s 10-Year Dividend Yield Range
Min: 1.51   Max: 5.39
Current: 2.49

1.51
5.39
Dividend Payout 0.72
SNY's Dividend Payout is ranked lower than
63% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. SNY: 0.72 )
SNY' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1
Current: 0.72

0.27
1
Dividend growth (3y) 4.90
SNY's Dividend growth (3y) is ranked higher than
79% of the 235 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNY: 4.90 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: 4.9

0
22.1
Yield on cost (5-Year) 3.31
SNY's Yield on cost (5-Year) is ranked higher than
92% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. SNY: 3.31 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 2   Max: 7.15
Current: 3.31

2
7.15
Share Buyback Rate -0.80
SNY's Share Buyback Rate is ranked higher than
79% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. SNY: -0.80 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.40
SNY's Price/Tangible Book is ranked lower than
86% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. SNY: 23.40 )
SNY' s 10-Year Price/Tangible Book Range
Min: 7.22   Max: 41.27
Current: 23.4

7.22
41.27
Price/DCF (Projected) 0.90
SNY's Price/DCF (Projected) is ranked higher than
92% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. SNY: 0.90 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.61   Max: 1.21
Current: 0.9

0.61
1.21
Price/Median PS Value 1.10
SNY's Price/Median PS Value is ranked higher than
67% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. SNY: 1.10 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 2.65
Current: 1.1

0.63
2.65
Price/Graham Number 5.20
SNY's Price/Graham Number is ranked lower than
72% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. SNY: 5.20 )
SNY' s 10-Year Price/Graham Number Range
Min: 1.88   Max: 5.54
Current: 5.2

1.88
5.54
Earnings Yield (Greenblatt) 4.90
SNY's Earnings Yield (Greenblatt) is ranked higher than
68% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNY: 4.90 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.6
Current: 4.9

0.5
10.6
Forward Rate of Return (Yacktman) 6.58
SNY's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. SNY: 6.58 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.4   Max: 62.9
Current: 6.58

7.4
62.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SNYNF.USA
Sanofi was incorporated under the laws of France in 1994. It is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions. The Company is engaged in offering solutions across areas of core historical strength and multiple growth platforms. Within its Pharmaceuticals business, it focuses on various areas which include diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields. The Company is facing competition from generics for several of its major products, in an environment subject to cost containment pressures from both third party payers and healthcare authorities. The manufacturing and research operations of the Company is subject to increasingly stringent health, safety and environmental (HSE) laws and regulations. The Company has core strengths in healthcare, with 7 growth platforms which includes diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Through the acquisition of Genzyme, the Company has strongly reinforced its footprint in rare diseases.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide